Our Partners and Us / The Shareholders
The Shareholders

Biochemtex

Biochemtex, a company of the Mossi Ghisolfi Group, is specialized in the design and construction of industrial plants in the petrochemical, polymers, fibers, energy, biofuels and environmental technologies sectors through its offices in Italy, USA, India and China. Biochemtex boasts 60 years of experience in process development and the commercialization of chemical plants.
The PROESA™ technology was developed in the laboratories of Biochemtex in Italy and the United States.
For further information:  www.biochemtex.com.

Novozymes

Novozymes is a world leader in the field of bio-innovation. Together with its clients covering a wide range of industries, Novozymes creates tomorrow's biotechnological solutions by improving its customers' business and the use of our planet's resources. With over 700 products used in 130 countries, Novozymes products allow to improve the industrial performances and to safeguard the global resources, offering superior and sustainable solutions for tomorrow's ever-changing market.
Novozymes, a biotech company headquartered in Denmark, is the leading global provider of enzymes to the biofuel industry. The commercial enzymes of the Cellic® series, allow, in particular, to competitively convert, also from the point of view of costs, the biomass into ethanol, and are widely regarded as the reference point of the sector.
For further information: www.novozymes.com.

TPG

TPG (Texas Pacific Group) Capital is a leading global private investment firm, founded in 1992 with $ 48B of assets under management and offices in San Francisco, Beijing, Fort Worth, Hong Kong, London, Luxembourg, Melbourne, Moscow, Mumbai, New York, Paris, Shanghai, Singapore and Tokyo. TPG has extensive experience with global public and private investments executed through leveraged buyouts, recapitalizations, spinouts, growth investments, joint ventures and restructurings.

TPG Biotech is part of the growth and equity investment platform of TPG. With more than $ 1 billion under management, TPG Biotech is specialized in investments in the pharmaceutical sector for the development and the discovery of new drugs, new medical technologies, diagnostics, healthcare and pharmaceutical services, the natural sciences and the industrial applications of biotechnologies.
For further information: www.tpg.com.